Soleil Downgrades Savient Pharma (SVNT) to Hold; Sees Limited Upside Despite Possible M&A Activity
Tweet Send to a Friend
Soleil Securities downgrades Savient Pharma (Nasdaq: SVNT) from Buy to Hold, price target moves from $21 to $23.
The ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
The ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
